These measures confer opposing effects on breast cancer risk, suggesting perturbed glycemic and/or other adverse effects of impaired GIPR signaling through this mechanism offset possible beneficial effects on insulin secretion and circulating testosterone levels. The gene discussed is GIPR; the disease is breast cancer.